Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

This study has been terminated.
(the fellow interested in this project left the institution)
Sponsor:
Collaborator:
Massachusetts General Hospital
Information provided by (Responsible Party):
Atul Malhotra, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01261377
First received: December 15, 2010
Last updated: April 30, 2013
Last verified: April 2013
  Purpose

Presence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in the same patient has been termed overlap syndrome, affecting 1% of the U.S. population. Despite the high prevalence of overlap syndrome, little research has been done in this field. Overlap syndrome has been recently reported to have higher death rate than COPD alone, which is due to effect on the heart. However, the mechanisms by which overlap syndrome affects the heart are not known well. Also, the ideal treatment for overlap syndrome is not known.

This study is being done to find the mechanisms by which overlap syndrome affects the right and left sides of heart (using cardiac MRI to study the heart). We will also compare the effect of treatment with bi-level positive airway pressure device (BPAP) vs. night-time oxygen on heart in overlap syndrome. These aims will allow us to test the hypothesis that overlap syndrome patients have worse heart function than COPD only or OSA only, and treatment with BPAP device will improve the heart function better than oxygen only.

At the baseline visit, the subject will undergo an overnight sleep study in the hospital. In the morning, blood draw to measure serum inflammatory biomarkers (C-Reactive Protein, interleukin-6, P-selectin, ICAM-1, TNF-alpha), urine catecholamine level, six-minute walk test, questionnaire for health-related quality of life score and modified Medical Research Council (MMRC) dyspnea score, lung function tests, ultrasound of forearm blood vessels and cardiac MRI will be done. No follow-up visit is needed if the subject does not have sleep apnea. If the subject has sleep apnea based on the sleep study, he/she will be allotted to treatment with a BPAP device or night-time oxygen for 6 months. If the subject does not want to be treated with BPAP or oxygen, CPAP device will be used to treat sleep apnea. During the duration of study treatment, phone calls and a brief study visit at 3 months will be done to make sure there is no discomfort related to the treatment. After 6 months of study treatment, cardiac MRI, ultrasound of forearm blood vessels, lung function tests, blood draw for serum inflammatory biomarkers, urine catecholamine level, six-minute walk test, and questionnaires for dyspnea score and quality of life score will be repeated.

This study will help us in better understanding of mechanisms of high death rate due to effects on the heart in overlap syndrome. It will also help us in understanding better ways to treat sleep apnea in COPD patients.


Condition Intervention Phase
Chronic Obstructive Airway Disease (COPD) With Co-existent Obstructive Sleep Apnea (Overlap Syndrome)
Device: Bi-level positive airway pressure (BPAP)
Drug: Oxygen
Device: CPAP
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Right ventricular end-diastolic volume [ Time Frame: Six months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Other cardiac hemodynamics parameters (end-systolic volume, ejection fraction, mass index and wall motion of right and left ventricles, coronary blood flow, pulmonary artery pressure and blood flow, etc.) [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Serum inflammatory biomarkers (C-reactive protein, interleukin-6, ICAM-1 and P-selectin) [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Urine catecholamine level [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Flow mediated dilatation of brachial artery [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Pulmonary Function tests [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • BODE Index [ Time Frame: Six months ] [ Designated as safety issue: No ]

Estimated Enrollment: 175
Study Start Date: November 2010
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Bi-level positive airway pressure (BPAP) Device: Bi-level positive airway pressure (BPAP)
The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
Active Comparator: Nocturnal oxygen Drug: Oxygen
Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
Active Comparator: Continuous positive airway pressure
The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
Device: CPAP
The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Both men and women with age more than 18 years.
  • Known diagnosis of COPD (GOLD stage 2 or higher).

Exclusion Criteria:

  • Already using CPAP or BPAP device.
  • Estimated GFR <30 ml/min/1.73 m2 or on hemodialysis.
  • Women known to be pregnant or planning to be pregnant in next 6 months.
  • Cardiac pacemaker, metallic heart valves, metallic implants, claustrophobic.
  • Chronic atrial fibrillation or frequent premature ventricular contractions.
  • Using lipid-lowering medications, aspirin, oral steroids, steroid-sparing medications or anti-oxidant vitamin supplements.
  • If taking sildenafil or related drugs, unable to stop it within 48 hours of the study visit.
  • Contraindications to stress cardiac testing: acute myocardial infarction within 48 hours, unstable angina not yet stabilized with medical therapy, ongoing chest pain, active broncho-constriction, uncontrolled cardiac arrhythmia, symptomatic severe aortic stenosis, aortic dissection, acute pulmonary embolism or pericarditis.
  • Uncontrolled COPD or acute COPD exacerbation.
  • Known chronic inflammatory diseases like lupus or active infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01261377

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Massachussets General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Brigham and Women's Hospital
Massachusetts General Hospital
Investigators
Principal Investigator: Atul Malhotra, MD Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Atul Malhotra, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01261377     History of Changes
Other Study ID Numbers: 2010-P001753
Study First Received: December 15, 2010
Last Updated: April 30, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Chronic obstructive airway disease, COPD, obstructive sleep apnea, OSA, BPAP, CPAP, positive airway pressure therapy, overlap syndrome

Additional relevant MeSH terms:
Apnea
Pulmonary Disease, Chronic Obstructive
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Lung Diseases, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Lung Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on July 28, 2014